What is the market's earnings forecast for Profound Medical next quarter?

What is Profound Medical's latest dividend and current dividend yield?

What factors drove the changes in Profound Medical's revenue and profit?

Did Profound Medical beat or miss consensus estimates last quarter?

What were the key takeaways from Profound Medical’s earnings call?

What is the revenue and EPS growth rate for Profound Medical year over year?

What does Profound Medical do and what are its main business segments?

What guidance did Profound Medical's management provide for the next earnings period?

- **Revenue Surge**: Q3 2025 revenue up 87% YoY to $5.3M, driven by TULSA-PRO adoption and AI software launch.
- **Margin Expansion**: Gross margin hits 74.3%, with path to 70%+ as scale economies take hold.
- **BPH Breakthrough**: New AI software enables 60-90 minute procedures, targeting 10%+ of total cases in 2026.
- **Sonalleve Growth**: 10+ global sites treating uterine diseases, with trials for pancreatic cancer expanding addressable market.
- **Profitability Path**: 70-75% YoY growth, 200+ TULSA-PRO sites by 2026, and cash flow positivity as revenue scales.

**【CFO Financial Commentary】**
- Q3 2025 revenue: $5.3M (87% YoY growth), with $4.1M recurring and $1.2M capital sales.
- Gross margin: 74.3% (vs. 63.1% in Q3 2024).
- Operating expenses: $12.8M (20% YoY increase due to R&D and commercial expansion).
- Net loss: $8M ($0.26/share) vs. $9.4M ($0.38/share) in Q3 2024.
- Cash balance: $24.8M, with plans to achieve cash flow positivity as revenue scales.

**【President’s Clinical Update】**
- **TULSA AI Volume Reduction Software Launch**: Full release at RSNA 2025, with pilot showing 60-90 minute procedures and surgeon satisfaction.
- **Kapton Trial Milestone**: All 160 patients treated, with 1-year safety and 3-year efficacy data to be presented at RSNA and SUO.
- **BPH Expansion**: Targeting 10%+ of total procedures in 2026, with TULSA days enabling multiple cases per day.

**【CCO Commercial Momentum】**
- 70 TULSA-PRO sites installed, with 93 systems in final sales pipeline stages (verify, negotiate, contract).
- **Reimbursement Progress**: Medicare payments ~$13,000/case, commercial payers up to $65,000/case post-appeal.
- **Partnerships**: 25-for-200 program driving early breakeven, with global deals in Saudi Arabia, Australia, and Japan.

**【CEO Strategic Vision】**
- **Trifecta Growth Plan**: 200 TULSA-PRO sites, 40+ installs/year, $85M+ annual revenue by 2026.
- **Sonalleve Expansion**: 10+ global sites treating uterine fibroids and adenomyosis, with trials for pancreatic cancer.
- **Profitability Path**: 70-75% YoY revenue growth, 70%+ gross margin, and path to profitability as scale economies kick in.

**【Q&A Highlights】**
- **Utilization Trend**: Q4 2025 procedures up 30%+ vs. Q3, driven by Medicare CPT-1 adoption and private payer wins.
- **Pipeline Conversion**: 50-65% of late-stage pipeline expected to close in 2025-2026, with 70+ sites by year-end.
- **Sonalleve Focus**: Expanding into body cavity oncology (liver, pancreas) with MR-guided focused ultrasound.

Profound Medical Corp. (PROF) Q3 2025 Earnings Call Transcript

- **Revenue Growth Target**: 70-75% YoY for 2025, driven by capital sales transition.
- **Gross Margin Expansion**: 73% in Q2 (vs. 64% YoY), reflecting recurring revenue strength.
- **Pipeline Confidence**: 80 qualified TULSA-PRO leads in final stages, with 75+ installations expected by year-end.
- **Clinical Success**: CAPTAIN trial completion; TULSA-AI BPH module pilot shows 60-90min procedure times.
- **Strategic Moves**: TULSA-PLUS compatibility testing complete; interventional MR adoption accelerating.

**【CFO Financial Commentary】**
- Q2 2025 total orders: $3.0M; revenue: $2.2M (flat YoY), with $1.6M recurring and $0.65M capital sales.
- Gross margin improved to 73% (vs. 64% Q2 2024), driven by higher recurring revenue mix.
- Operating expenses rose to $15.4M (vs. $9.3M YoY), leading to net loss of $15.7M ($0.52/share) vs. $6.9M ($0.28/share) in Q2 2024.
- Cash balance: $35.2M as of June 30, 2025.

**【Commercial Update】**
- TULSA-PRO pipeline: 500 prospects, 100+ engaged leads, 80 qualified (39 verifying, 27 negotiating, 14 contracting).
- Q2 revenue shortfall due to delayed capital sales; 70-75% YoY growth target remains for 2025.
- U.S. sales team streamlined: 3 regional directors with 3-4 reps each, focusing on grit and resiliency.
- Transitioning from placement to capital model; long-term mix expected to be 70% recurring, 30% capital.

**【Clinical & Product Updates】**
- CAPTAIN trial fully recruited (212 patients vs. target 201); perioperative data shows TULSA reduces recovery time by 2 weeks vs. robotic surgery.
- TULSA-AI volume reduction module pilot launched in Q2; full commercialization planned for Q4 2025.
- BPH trial results: 76% IPSS reduction, 96% medication discontinuation, no Grade 4 adverse events.

**【CEO Summary】**
- Confident in 70-75% YoY revenue growth for 2025, driven by capital sales and recurring revenue.
- TULSA-PRO utilization up 10% Q1-Q2; reimbursement impact expected to accelerate in H2.
- TULSA-PLUS with interventional MRs: 1+ installations expected by year-end, with compatibility testing complete for Q4.

**【Q&A Highlights】**
- **Sales Funnel**: 80% of qualified leads in final stages; average time from contracting to install ~3-4 months.
- **Reimbursement**: TULSA maintains favorable RVUs vs. BPH competitors; Aquablation codes downgraded.
- **TULSA-PLUS**: Economic model compelling; Cook Medical's IMRI division driving interventional MR adoption.
- **Clinical Trials**: CARE Registry expanding; site-specific studies show better outcomes than TACT trial.
- **Competition**: TULSA's no blood loss/no overnight stay differentiate from systemic therapies targeting localized disease.

Profound Medical Corp. (PROF) Q2 2025 Earnings Call Transcript

- **Revenue Growth**: Q1 2025 revenue surges 82% to $2.6M, driven by recurring sales and capital equipment.
- **Clinical Superiority**: CAPTAIN trial proves TULSA-PRO outperforms robotic surgery with 0% blood loss and 24-hour recovery.
- **Market Expansion**: New BPH module and TULSA+ program target 10M+ patients and 250+ urology practices.
- **Financial Momentum**: 70-75% YoY growth expected, backed by $46.4M cash and Siemens MRI partnership.

**【CFO Financial Summary】**
- Q1 2025 revenue: $2.6 million (82% YoY growth), with $1.8M recurring and $0.8M capital sales.
- Gross margin improved to 71% (vs. 60% Q1 2024).
- Operating expenses: $13M (55% YoY increase) due to R&D and commercial expansion.
- Net loss: $10.7M ($0.36/share) vs. $6.6M ($0.27/share) in Q1 2024.
- Cash balance: $46.4M as of March 31, 2025.

**【COO Clinical Updates】**
- **CAPTAIN Trial Results**: TULSA-PRO demonstrated superior patient outcomes vs. robotic prostatectomy, including:
  - 0% blood loss vs. 100% in robotic surgery.
  - 24-hour hospital stay reduction (most treated outpatient).
  - 0% grade 4 adverse events.
  - 30% faster recovery time.
- **BPH Module Launch**: AI-driven volume reduction module for benign prostatic hyperplasia, with limited release in June and full launch Q4 2025.

**【CCO Commercial Strategy】**
- **TULSA+ Program**: Turnkey solution for urologists without existing MRI infrastructure, featuring:
  - Siemens Magnetom FreeMax 0.55T MRI (80cm bore, 250sqft footprint).
  - Economic model: 2 TULSA procedures/week cover capital costs.
  - Flexible deployment options (mobile or permanent).
- **Reimbursement**: CMS Level 7 codes effective Jan 1, 2025, with higher reimbursement rates than competitors.

**【CEO Strategic Vision】**
- TULSA-PRO is the first MR-guided prostate ablation with Level 1 clinical evidence (CAPTAIN trial).
- BPH module expands addressable market by 3x (10M+ patients globally).
- TULSA+ program enables rapid adoption in 250+ urology practices.
- 2025 revenue growth target: 70-75% YoY, driven by capital sales and procedure volume.
- Siemens partnership to accelerate MR adoption in urology.


Profound Medical Corporation (PROF) Q1 2025 Earnings Conference Call Transcript

- **Record Q4 Performance**: $4.2M revenue (+108% YoY), 71% gross margin, lowest net loss in 5 years.
- **TULSA-PRO Differentiation**: Precision ablation for 2/3 prostate cancer patients, unmatched by competitors.
- **Growth Engine**: 2025 targets 70-75% revenue growth, 2026+ triple-digit expansion with TULSA-PLUS.
- **Clinical Milestone**: CAPTAIN trial data expected at AUA 2025, BPH module demo in April.


**【CFO Financial Summary】**
- Q4 2024 revenue: $4.2 million (108% YoY growth), with $2.7 million recurring and $1.5 million capital sales.
- Gross margin: 71% (vs. 52% Q4 2023), driven by product mix.
- Net loss: $4.9 million (-45% YoY), lowest since Q1 2020.
- Cash balance: $54.9 million as of Dec 31, 2024.

**【President's Clinical Update】**
- TULSA-PRO precision: 1.3mm ablation accuracy, real-time thermometry control.
- Addressable market: 2/3 of prostate cancer patients (diffuse/multifocal or edge lesions).
- CAPTAIN trial: 201 patients randomized, 174 treated/scheduled, targeting AUA 2025 data release.

**【Commercial Strategy】**
- Transitioned to capital sales model, Q4 2024 capital sales: $1.5 million.
- Global team rebuild: 50+ professionals from Stryker, Intuitive Surgical, etc.
- 2025 goals: 70-75% revenue growth, 2026+ triple-digit growth.
- TULSA-PLUS launch: Q2 2025, combining TULSA-PRO with Siemens MRI system.

**【CEO Vision】**
- 2025 priorities: CAPTAIN perioperative data, BPH AI module launch, TULSA-PLUS rollout.
- BPH market expansion: 400k annual patients (vs. 200k prostate cancer), no hospital stay needed.
- Economic advantage: APC Level 7 codes (vs. peers' Level 6), broader reimbursement settings.


PROF

PROF fundamentals

Earnings Call

You can ask Aime